Has Adaobi Obasi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,585 in general payments to Adaobi Obasi, MD across 66 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Adaobi Obasi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Adaobi Obasi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Adaobi Obasi, MD

Dermatopathology · Laredo, TXNPI 1831417211

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 75.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $5,325 and has fallen 97.9% since, to $114 in 2025.

$7,585in general payments, 2019–2025

Across 66 payments — averaging $114.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$6K
Johnson & Johnson$604
Galderma Laboratories, L.p.$575
Arcutis Biotherapeutics, Inc.$149
Ortho Dermatologics, A Division Of Bausch Health US, LLC$123
Sanofi$97
plus $317 from 9 others

$118,576in research payments, 2019–2025

Across 18 payments — averaging $6587.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$74K
Eli Lilly$26K
UCB SA$18K

What the payments were for

Speaking & faculty fees$4,10054%
Travel & lodging$1,42519%
Food & beverage$1,57221%
Education$4886%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	9	$5,721
Johnson & Johnson	17	$604
Galderma Laboratories, L.p.	16	$575
Arcutis Biotherapeutics, Inc.	1	$149
Ortho Dermatologics, A Division Of Bausch Health US, LLC	1	$123
Sanofi	4	$97
Strata Skin Sciences, Inc.	5	$54
Incyte Corporation	1	$52
VYNE Pharmaceuticals Inc.	3	$51
Aclaris Therapeutics, Inc.	2	$43
Bristol Myers Squibb	2	$33
Dermira, Inc.	2	$31
Novartis	1	$22
Lilly USA, LLC	1	$18
Organon	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EUCRISA$5,640
EPIDUO FORTE$167
SOOLANTRA$167
ORACEA$167
SILIQ$123
TARGRETIN$123
ARAZLO$123

How this compares

$7,585 in reported general payments places this provider in the 70th percentile of 54 dermatopathology providers in Texas.

See all dermatopathology providers in Texas →

Medicare billing

Part B allowed, 2024

$71,193

Medicare patients

194

Services billed

866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OtezlaApremilast	46	$218,748
Metronidazole	120	$8,189
Ammonium Lactate	437	$7,831
Azelaic Acid	66	$6,943
Ketoconazole	391	$4,828
Tacrolimus	60	$4,464
Fluocinolone Acetonide	72	$3,096
Mometasone Furoate	159	$2,645
Triamcinolone Acetonide	80	$1,681
Mupirocin	164	$1,365
Ciclopirox	30	$1,322
Calcipotriene	12	$1,277
Fluocinonide	41	$1,195
Clobetasol Propionate	43	$1,176
Desonide	24	$781

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Laredo

Angela MooreArlington$423K
Melissa ChiangSpring$163K
Alde GavinoLiberty Hill$110K
Clay CockerellDallas$40K
Michael TetzlaffHoustion$38K
Matthew PetittPasadena$23K
Miranda EwelukwaSugar Land$22K
Ronald HarrisAustin$14K
Andrew FischerHouston$11K
Titilola SodeDallas$11K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →